Disabling of receptor activator of nuclear factor-κB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo.
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
The tumor necrosis factor family ligand, tumor necrosis factor-related activation-induced cytokine (TRANCE), and its receptors, receptor activator of nuclear factor-kappaB (RANK) and osteoprotegerin (OPG), are known to be regulators of development and activation of osteoclasts in bone remodeling. Sustained osteoclast activation that occurs through TRANCE-RANK causes osteopenic disorders such as osteoporosis and contributes to osteolytic metastases. Here, we report a rationally designed small molecule mimic of osteoprotegerin to inhibit osteoclast formation in vitro and limit bone loss in an animal model of osteoporosis. One of the mimetics, OP3-4, significantly inhibited osteoclast formation in vitro (IC(50) = 10 microm) and effectively inhibited total bone loss in ovariectomized mice at a dosage of 2 mg/kg/day. Unlike soluble OPG receptors, which preclude TRANCE binding to RANK, OP3-4 shows the ability to modulate RANK-TRANCE signaling pathways and alters the biological functions of the RANK-TRANCE receptor complex by facilitating a defective receptor complex. These features suggest that OPG-derived small molecules can be used as a probe to understand complex biological functions of RANK-TRANCE-OPG receptors and also can be used as a platform to develop more useful therapeutic agents for inflammation and bone disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This small molecule mimic of OPG was delivered continuously by osmotic minipump for 28 d immediately after mice were ovariectomized, and this approach led to partial prevention of OVX-related bone loss ( 206).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [206]
Citations
Cites
The protein data bank: A computer-based archival file for macromolecular structures
Bernstein, F. C., Koetzle, T. F., Williams, G. J. B., Meyer, E. F., Brice, M. D., Rodgers, J. R., Kennard, O., Shimanouchi, T., & Tasumi, M. (1977) · Journal of Molecular Biology · doi:10.1016/s0022-2836(77)80200-3 · Cited by 8,578
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
The TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650
NF-κB at the crossroads of life and death
Karin, M., & Lin, A. (2002) · Nature Immunology · doi:10.1038/ni0302-221 · Cited by 2,709
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Minireview: The OPG/RANKL/RANK System
Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515
Kobayashi, K., Takahashi, N., Jimi, E., Udagawa, N., Takami, M., Kotake, S., Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.275 · Cited by 1,304
Self-citationOsteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,184
TNF? and the TNF receptor superfamily: Structure-function relationship(s)
Idriss, H. T., & Naismith, J. H. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20000801)50:3<184::aid-jemt2>3.0.co;2-h · Cited by 1,183
Banner, D. W., D'Arcy, A., Janes, W., Gentz, R., Schoenfeld, H.-J., Broger, C., Loetscher, H., & Lesslauer, W. (1993) · Cell · doi:10.1016/0092-8674(93)90132-a · Cited by 1,104
The molecular architecture of the TNF superfamily
Bodmer, J.-L., Schneider, P., & Tschopp, J. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01995-8 · Cited by 916
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825
RANK-L and RANK: T Cells, Bone Loss, and Mammalian Evolution
Theill, L. E., Boyle, W. J., & Penninger, J. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064753 · Cited by 819
TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis.
Pettit, A. R., Ji, H., von Stechow, D., Müller, R., Goldring, S. R., Choi, Y., Benoist, C., & Gravallese, E. M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63016-7 · Cited by 807
Self-citationRANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis
Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9788 · Cited by 746
Self-citationTumor Necrosis Factor-α Induces Differentiation of and Bone Resorption by Osteoclasts
Azuma, Y., Kaji, K., Katogi, R., Takeshita, S., & Kudo, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.7.4858 · Cited by 731
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689
Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
Hofbauer, L. C., & Heufelder, A. E. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100226 · Cited by 586
Efficiency of signalling through cytokine receptors depends critically on receptor orientation
Syed, R. S., Reid, S. W., Li, C., Cheetham, J. C., Aoki, K. H., Liu, B., Zhan, H., Osslund, T. D., Chirino, A. J., Zhang, J., et al. (1998) · Nature · doi:10.1038/26773 · Cited by 551
Min, H., Morony, S., Sarosi, I., Dunstan, C. R., Capparelli, C., Scully, S., Van, G., Kaufman, S., Kostenuik, P. J., Lacey, D. L., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.463 · Cited by 550
Eck, M. J., & Sprang, S. R. (1990) · PubMed · doi:10.2210/pdb1tnf/pdb · Cited by 507
Definition of general topological equivalence in protein structures
S̆ali, A., & Blundell, T. L. (1990) · Journal of Molecular Biology · doi:10.1016/0022-2836(90)90134-8 · Cited by 501
The effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484
The Structure of Tumor Necrosis Factor-α at 2.6 Å Resolution
Eck, M. J., & Sprang, S. R. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)71533-0 · Cited by 473
Characterization of the Intracellular Domain of Receptor Activator of NF-κB (RANK)
Darnay, B. G., Haridas, V., Ni, J., Moore, P. A., & Aggarwal, B. B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20551 · Cited by 413
RANK Ligand and Osteoprotegerin: Paracrine Regulators of Bone Metabolism and Vascular Function
Schoppet, M., Preissner, K. T., & Hofbauer, L. C. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000012303.37971.da · Cited by 405
Jimi, E., Akiyama, S., Tsurukai, T., Okahashi, N., Kobayashi, K., Udagawa, N., Nishihara, T., Takahashi, N., & Suda, T. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.434 · Cited by 404
Stüber, E., Neurath, M., Calderhead, D., Perry Fell, H., & Strober, W. (1995) · Immunity · doi:10.1016/1074-7613(95)90031-4 · Cited by 390
Body, J.-J., Greipp, P., Coleman, R. E., Facon, T., Geurs, F., Fermand, J.-P., Harousseau, J.-L., Lipton, A., Mariette, X., Williams, C. D., et al. (2003) · Cancer · doi:10.1002/cncr.11138 · Cited by 383
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Croucher, P. I. (2001) · Blood · doi:10.1182/blood.v98.13.3534 · Cited by 377
Srivastava, S., Toraldo, G., Weitzmann, M. N., Cenci, S., Ross, F. P., & Pacifici, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010764200 · Cited by 358
Josien, R., Li, H.-L., Ingulli, E., Sarma, S., R.Wong, B., Vologodskaia, M., Steinman, R. M., & Choi, Y. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.3.495 · Cited by 334
Self-citationLee, S. E., Woo, K. M., Kim, S. Y., Kim, H.-M., Kwack, K., Lee, Z. H., & Kim, H.-H. (2002) · Bone · doi:10.1016/s8756-3282(01)00657-3 · Cited by 311
Pancreatic Lymph Node-Derived CD4+CD25+ Treg Cells
Green, E. A., Choi, Y., & Flavell, R. A. (2002) · Immunity · doi:10.1016/s1074-7613(02)00279-0 · Cited by 310
Self-citationOsteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
Holen, I., Croucher, P. I., Hamdy, F. C., & Eaton, C. L. (2002) · PubMed · Cited by 270
Tumor Necrosis Factor-α Supports the Survival of Osteoclasts through the Activation of Akt and ERK
Lee, S. E., Chung, W. J., Kwak, H. B., Chung, C.-H., Kwack, K., Lee, Z. H., & Kim, H.-H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103642200 · Cited by 254
Stimulation by Toll-Like Receptors Inhibits Osteoclast Differentiation
Takami, M., Kim, N., Rho, J., & Choi, Y. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.3.1516 · Cited by 250
Self-citationModularity in the TNF-receptor family
Naismith, J. H., & Sprang, S. R. (1998) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(97)01164-x · Cited by 248
TRANCE is a TNF family member that regulates dendritic cell and osteoclast function
Wong, B. R., Josien, R., & Choi, Y. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.65.6.715 · Cited by 232
Self-citationRole of RANKL and RANK in bone loss and arthritis
Jones, D. H., Kong, Y.-Y., & Penninger, J. M. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.suppl_2.ii32 · Cited by 223
Livnah, O., Johnson, D. L., Stura, E. A., Farrell, F. X., Barbone, F. P., You, Y., Liu, K. D., Goldsmith, M. A., He, W., Krause, C. D., et al. (1998) · Nature Structural Biology · doi:10.1038/2965 · Cited by 217
Walsh, M. C., & Choi, Y. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00027-3 · Cited by 200
Self-citationPark, B.-W., Zhang, H.-T., Wu, C., Berezov, A., Zhang, X., Dua, R., Wang, Q., Kao, G., O'Rourke, D. M., Greene, M. I., et al. (2000) · Nature Biotechnology · doi:10.1038/72651 · Cited by 199
Self-citationStructure of antibody hypervariable loops reproduced by a conformational search algorithm
Bruccoleri, R. E., Haber, E., & Novotný, J. (1988) · Nature · doi:10.1038/335564a0 · Cited by 196
Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity
Lam, J., Nelson, C. A., Ross, F. P., Teitelbaum, S. L., & Fremont, D. H. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13890 · Cited by 194
Crystallographic Evidence for Dimerization of Unliganded Tumor Necrosis Factor Receptor
Naismith, J. H., Devine, T. Q., Brandhuber, B. J., & Sprang, S. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.13303 · Cited by 190
The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution.
Eck, M. J., Ultsch, M., Rinderknecht, E., de Vos, A. M., & Sprang, S. R. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45849-8 · Cited by 187
Weitzmann, M. N., Cenci, S., Rifas, L., Haug, J., Dipersio, J., & Pacifici, R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.328 · Cited by 164
Mühlenbeck, F., Schneider, P., Bodmer, J.-L., Schwenzer, R., Hauser, A., Schubert, G., Scheurich, P., Moosmayer, D., Tschopp, J., & Wajant, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000482200 · Cited by 154
Apoptotic, non-apoptotic, and anti-apoptotic pathways of tumor necrosis factor signalling
Natoli, G., Costanzo, A., Guido, F., Moretti, F., & Levrero, M. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00154-3 · Cited by 153
Gudbjornsson, B., Juliusson, U. I., & Gudjonsson, F. V. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.1.32 · Cited by 152
Biosynthetic Human Parathyroid Hormone (1-34) Effects on Bone Quality in Aged Ovariectomized Rats
Sato, M., Zeng, G. Q., & Turner, C. H. (1997) · Endocrinology · doi:10.1210/endo.138.10.5440 · Cited by 147
Cha, S., Sung, B., Kim, Y., Song, Y.-L., Kim, H.-J., Kim, S., Lee, M., & Oh, B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004414200 · Cited by 145
Arron, J. R., Vologodskaia, M., Wong, B. R., Naramura, M., Kim, N., Gu, H., & Choi, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100414200 · Cited by 127
Self-citationTakasaki, W., Kajino, Y., Kajino, K., Murali, R., & Greene, M. I. (1997) · Nature Biotechnology · doi:10.1038/nbt1197-1266 · Cited by 121
Self-citationBerezov, A., Zhang, H.-T., Greene, M. I., & Murali, R. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000527m · Cited by 107
Self-citationAtkins, G. J., Bouralexis, S., Haynes, D. R., Graves, S. E., Geary, S. M., Evdokiou, A., Zannettino, A. C. W., Hay, S., & Findlay, D. M. (2001) · Bone · doi:10.1016/s8756-3282(01)00404-5 · Cited by 105
Michigami, T., Ihara-Watanabe, M., Yamazaki, M., & Ozono, K. (2001) · PubMed · Cited by 96
Crystal Structure of the Extracellular Domain of Mouse RANK Ligand at 2.2-Å Resolution
Ito, S., Wakabayashi, K., Ubukata, O., Hayashi, S., Okada, F., & Hata, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106525200 · Cited by 74
Lee, Z. H., Kwack, K., Kim, K. K., Lee, S. H., & Kim, H. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.6.1536 · Cited by 66
Shiotani, A., Takami, M., Itoh, K., Shibasaki, Y., & Sasaki, T. (2002) · The Anatomical Record · doi:10.1002/ar.10121 · Cited by 62
Self-citationRamachandran, G. N., & Venkatachalam, C. M. (1968) · Biopolymers · doi:10.1002/bip.1968.360060903 · Cited by 60
RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse
Mori, H., Kitazawa, R., Mizuki, S., Nose, M., Maeda, S., & Kitazawa, S. (2002) · Histochemistry and Cell Biology · doi:10.1007/s00418-001-0376-9 · Cited by 58
Biggs, T. E., Baker, S. T., Botham, M. S., Dhital, A., Barton, C. H., & Perry, V. H. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200107)31:7<2060::aid-immu2060>3.0.co;2-l · Cited by 53
Self-citationReceptor activator of nuclear factor κB ligand (RANKL): another link between breast and bone
Martin, T. J., & Gillespie, M. T. (2001) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(00)00351-9 · Cited by 49
Zhang, K. Y. J., & Eisenberg, D. S. (1994) · Protein Science · doi:10.1002/pro.5560030416 · Cited by 48
Andersson, N., Lindberg, M. K., Ohlsson, C., Andersson, K., & Ryberg, B. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1700529 · Cited by 43
Auger, G. A., Pease, J. E., Shen, X., Xanthou, G., & Barker, M. D. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200204)32:4<1003::aid-immu1003>3.0.co;2-p · Cited by 39
Fas Aggregation Does Not Correlate with Fas-Mediated Apoptosis
Lee, Y.-J., & Shacter, E. B. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.1.82 · Cited by 30
Structure-based design of immunologically active therapeutic peptides
Murali, R., & Greene, M. I. (1998) · Immunologic Research · doi:10.1007/bf02786441 · Cited by 26
Self-citationTumor necrosis factor receptor superfamily.
Naismith, J. H., & Sprang, S. R. (1997) · PubMed · Cited by 22
Advances in the Treatment of Osteoporosis
Bell, N. H. (2001) · Current Drug Targets - Immune Endocrine & Metabolic Disorders · doi:10.2174/1568008013341622 · Cited by 16
Research works printed but not linked: 6
- Michigami, 2001, Cancer Res., 61, 1637
- Wang, 2002, Eur. J. Immunol., 32, 1090, 10.1002/1521-4141(200204)32:4<1090::AID-IMMU1090>3.0.CO;2-P · DOI · Paper page
- Naismith, 1995, J. Inflamm., 47, 1
- Choi, 2001, Eur. J. Immunol., 31, 2179, 10.1002/1521-4141(200107)31:7<2179::AID-IMMU2179>3.0.CO;2-X · DOI
- Holen, 2002, Cancer Res., 62, 1619
- Eghbali-Fatourechi, 2003, J. Clin. Invest., 111, 1221, 10.1172/JCI200317215 · doi:10.1172/jci200317215 · Paper page
Cited by
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
Hofbauer, L. C. (2004) · JAMA · doi:10.1001/jama.292.4.490 · Cited by 988
Stenvinkel, P., Ketteler, M., Johnson, R. J., Lindholm, B., Pecoits-Filho, R., Riella, M., Heimbürger, O., Cederholm, T., & Girndt, M. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00200.x · Cited by 932
“Last, since OPG is likely to possess calcification inhibitory capacity, the development of anti-osteoporotic OPG peptidomimetics may facilitate protective effects with regard to the vascular wall calcifications [160].”
BackgroundKearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Theoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663
Survey of the year 2003 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2005) · Journal of Molecular Recognition · doi:10.1002/jmr.726 · Cited by 505
Metadata
- Authors
- Cheng, X., Kinosaki, M., Takami, M., Choi, Y., Zhang, H., & Murali, R.
- Affiliations
- University of Pennsylvania (US)
- Abramson Cancer Center (US)
- Corresponding author
- Murali, Ramachandran
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-02
- Volume
- 279
- Issue
- 9
- Pages
- 8269-8277
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2073112480
- Cited by
- 92
- References
- 74
- Citations by year
- 2024: 2 · 2023: 3 · 2022: 5 · 2021: 3 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 3 · 2016: 4 · 2015: 2 · 2014: 2 · 2013: 4 · 2012: 3
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6100 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- RANK, osteoprotegerin, trance, osteoclastogenesis, bone loss, osteoporosis, peptidomimetics, ovariectomized mice, bone remodeling, osteolytic bone metastasis
- MeSH terms
- Amino Acid Sequence, Animals, Binding Sites, Bone Resorption, Carrier Proteins, Disease Models, Animal, Female, Glycoproteins, Kinetics, Membrane Glycoproteins, Mice, Inbred C57BL, Models, Molecular, Oligopeptides, Osteoclasts, Osteoporosis, Ovariectomy, Peptide Fragments, Signal Transduction, NF-kappa B, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Mice, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.